Patents by Inventor Martin S. Springer

Martin S. Springer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Eosinophil eotaxin receptor
    Publication number: 20020192214
    Abstract: The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human &bgr;-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.
    Type: Application
    Filed: August 6, 2001
    Publication date: December 19, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Bruce L. Daugherty, Julie A. Demartino, Salvatore J. Siciliano, Martin S. Springer
  • Eosinophil eotaxin receptor
    Patent number: 6271347
    Abstract: The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human &bgr;-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.
    Type: Grant
    Filed: April 24, 1997
    Date of Patent: August 7, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Bruce L. Daugherty, Julie A. Demartino, Salvatore J. Siciliano, Martin S. Springer
  • Spiro-substituted azacycles as modulators of chemokine receptor activity
    Patent number: 6013644
    Abstract: The present invention is directed spiro-substituted azacycles of formula I: (wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, k, l and m are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: January 11, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Sander G. Mills, Malcolm Maccoss, Martin S. Springer
  • Spiro-substituted azacycles as modulators of chemokine receptor activity
    Patent number: 5962462
    Abstract: The present invention is directed to spiro-substituted azacycles of the Formula 1: ##STR1## (wherein R.sub.1, l, m, Q, W, X, Y, and Z are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: October 5, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Sander G. Mills, Malcolm Maccoss, Martin S. Springer
  • Substituted aminoquinolines as modulators of chemokine receptor activity
    Patent number: 5919776
    Abstract: The present invention is directed to aminoquinolines of Formula I: ##STR1## (wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: July 6, 1999
    Assignee: Merck & Co., Inc.
    Inventors: William K. Hagmann, Martin S. Springer
  • Assay to identify human C5a antagonists and agonists
    Patent number: 5614370
    Abstract: The invention is an assay, including a series of peptides, which allow screening for inhibitors of C5a binding targeted to the subsite on the C5a receptor occupied by the C-terminus of C5a. These peptides allow compound testing efforts to be targeted to this same subsite so that C5a agonists and antagonists can be identified. These peptides have much greater affinity (Ki<10 nM) than does the natural C-terminus of C5a (Ki=300 .mu.M) and have been labeled to allow for detection of molecules which inhibit binding of these peptides at this receptor subsite. The invention is useful to develop agonists, partial agonists, and antagonists of C5a, and the invention includes compounds identified according to the method of this invention and methods of their use.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: March 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Zenon Konteatis, Salvatore J. Siciliano, Martin S. Springer
  • Purified C5a receptor from human polymorphonuclear leukocytes
    Patent number: 5177190
    Abstract: A method is disclosed for isolating and purifying C5a receptor from human polymorphonuclear leukocytes. C5a is a complement-derived protein which is important as a mediator of inflammatory responses. C5a receptor may be used to screen create and quantify C5a antagonists useful as anti-inflammatory agents and immunoregulants and to generate monoclonal and polyclonal anti-C5a receptor antibodies useful as anti-inflammatory agents and immunoregulants.
    Type: Grant
    Filed: January 22, 1992
    Date of Patent: January 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Thomas E. Rollins, Martin S. Springer